We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Osteopontin as a Biomarker for Ovarian Cancer

Anthony O'Regan, MD; Catherine Fleming, MD, MPH
JAMA. 2002;287(24):3208-3210. doi:10.1001/jama.287.24.3206.
Text Size: A A A
Published online


To the Editor: Dr Kim and colleagues1 found elevated serum osteopontin levels in patients with ovarian carcinoma. While the authors' approach has high sensitivity, the nonspecific nature of osteopontin expression in many diseases limits the potential clinical application of serum osteopontin as a unique biomarker for ovarian cancer.

Test specificity is central to any biomarker or screening program. Osteopontin may be expressed in many inflammatory and noninflammatory diseases including cancers of varied tissue origin.2,3 Although a variety of cell types express osteopontin, macrophages are a major source.2 Even in carcinoma, there is evidence that infiltrating macrophages rather than tumor cells are the principal source of osteopontin.3 Prior investigations have shown very high levels of osteopontin in hemodialysis patients with arterial atherosclerosis and in patients with gram-negative sepsis.4 These studies suggest that assays of total serum osteopontin alone will lack sufficient specificity to be a clinically applicable cancer biomarker.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

5 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.